Mesna
Acute Lymphoblastic Leukemia
Center for International Blood and Marrow Transplant ResearchSmall moleculePhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 65/ 100
Competitive context
246 Active assets in the Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PERIPHERAL BLOOD STEM CELLS, ALLOGENEIC, CD34 POSITIVE Fred Hutchinson Cancer Center | Phase 2/3 | BBB |
Gm-Csf Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Phase 4 | BBB |
Equine Atg Instituto Nacional de Cancer, Brazil | Phase 3 | BBB |
THIOGUANINE ANHYDROUS St. Jude Children's Research Hospital | Phase 4 | BBB |
Cyclophosphamide Sawa Ito, MD | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Mesna is also rated in:
disease related to hematopoietic stem cell transplantActive
BB
Indicative · Phase 2
69 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →